A highly potential cleavable linker for tumor targeting antibody-chemokines

References

• Abbas, A. K., Lichtman, A. H., & Pillai, S. (2014). Cellular and molecular immunology E-book. Elsevier Health Sciences.
   Google Scholar
• Abraham, M. J., Murtola, T., Schulz, R., Páll, S., Smith, J. C., Hess, B., & Lindahl, E. (2015). GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX, 1-2, 19–25.
   Google Scholar
• Amet, N., Lee, H.-F., & Shen, W.-C. (2009). Insertion of the designed helical linker led to increased expression of tf-based fusion proteins. Pharmaceutical Research, 26(3), 523–528. https://doi.org/https://doi.org/10.1007/s11095-008-9767-0
   PubMed Web of Science ®Google Scholar
• Amet, N., Wang, W., & Shen, W.-C. (2010). Human growth hormone-transferrin fusion protein for oral delivery in hypophysectomized rats. Journal of Controlled Release, 141(2), 177–182. https://doi.org/https://doi.org/10.1016/j.jconrel.2009.09.007
   PubMed Web of Science ®Google Scholar
• Argos, P. (1990). An investigation of oligopeptides linking domains in protein tertiary structures and possible candidates for general gene fusion. Journal of Molecular Biology, 211(4), 943–958. https://doi.org/https://doi.org/10.1016/0022-2836(90)90085-Z
   PubMed Web of Science ®Google Scholar
• Béguin, P. (1999). Hybrid enzymes. Current Opinion in Biotechnology, 10(4), 336–340.
   PubMed Web of Science ®Google Scholar
• Bell, M. R., Engleka, M. J., Malik, A., & Strickler, J. E. (2013). To fuse or not to fuse: What is your purpose? Protein Science, 22(11), 1466–1477. https://doi.org/https://doi.org/10.1002/pro.2356
   PubMed Web of Science ®Google Scholar
• Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., & Bourne, P. E. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235–242. https://doi.org/https://doi.org/10.1093/nar/28.1.235
   PubMed Web of Science ®Google Scholar
• Challita-Eid, P. M., Abboud, C. N., Morrison, S. L., Penichet, M. L., Rosell, K. E., Poles, T., Hilchey, S. P., Planelles, V., & Rosenblatt, J. D. (1998). A RANTES-antibody fusion protein retains antigen specificity and chemokine function. Journal of Immunology, 161(7), 3729–3736.
   PubMed Web of Science ®Google Scholar
• Chan, C. W. H., Law, B. M. H., So, W. K. W., Chow, K. M., & Waye, M. M. Y. (2017). Novel strategies on personalized medicine for breast cancer treatment: An update. International Journal of Molecular Sciences, 18(11), 2423.
   Web of Science ®Google Scholar
• Chen, X., Bai, Y., Zaro, J. L., & Shen, W.-C. (2010). Design of an in vivo cleavable disulfide linker in recombinant fusion proteins. BioTechniques, 49(1), 513–518. https://doi.org/https://doi.org/10.2144/000113450
   PubMed Web of Science ®Google Scholar
• Chen, X., Zaro, J. L., & Shen, W.-C. (2013). Fusion protein linkers: Property, design and functionality. Advanced Drug Delivery Reviews, 65(10), 1357–1369. https://doi.org/https://doi.org/10.1016/j.addr.2012.09.039
   PubMed Web of Science ®Google Scholar
• Comeau, S. R., Gatchell, D. W., Vajda, S., & Camacho, C. J. (2004). ClusPro: An automated docking and discrimination method for the prediction of protein complexes. Bioinformatics, 20(1), 45–50. https://doi.org/https://doi.org/10.1093/bioinformatics/btg371
   PubMed Web of Science ®Google Scholar
• Danø, K., Moller, V., Ossowski, L., & Nielsen, L. S. (1980). Purification and characterization of a plasminogen activator from mouse cells transformed by an oncogenic virus. Biochimica et Biophysica Acta (BBA) - Enzymology, 613(2), 542–555.
   PubMedGoogle Scholar
• Duncan, R., & Ulbrich, K. (1993). Development of N‐(2‐hydroxypropyl) methacrylamide copolymer conjugates for delivery of cancer chemotherapy. Makromolekulare Chemie Macromolecular Symposia, 70(1), 157–162.
   Google Scholar
• Elkins, P. A., Ho, Y. S., Smith, W. W., Janson, C. A., D'Alessio, K. J., McQueney, M. S., Cummings, M. D., & Romanic, A. M. (2002). Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallographica. Section D, Biological Crystallography, 58(Pt 7), 1182–1192. https://doi.org/https://doi.org/10.1107/s0907444902007849
   PubMedGoogle Scholar
• Fiser, A., & Sali, A. (2003). Modeller: Generation and refinement of homology-based protein structure models. Methods in Enzymology, 374, 461–491.
   PubMed Web of Science ®Google Scholar
• Frederickson, M., Callaghan, O., Chessari, G., Congreve, M., Cowan, S. R., Matthews, J. E., McMenamin, R., Smith, D.-M., Vinković, M., & Wallis, N. G. (2008). Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. Journal of Medicinal Chemistry, 51(2), 183–186. https://doi.org/https://doi.org/10.1021/jm701359z
   PubMed Web of Science ®Google Scholar
• Gillessen, S., Gnad-Vogt, U. S., Gallerani, E., Beck, J., Sessa, C., Omlin, A., Mattiacci, M. R., Liedert, B., Kramer, D., Laurent, J., Speiser, D. E., & Stupp, R. (2013). A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. European Journal of Cancer, 49(1), 35–44. https://doi.org/https://doi.org/10.1016/j.ejca.2012.07.015
   PubMed Web of Science ®Google Scholar
• Guo, J.-Q., Chen, L., Ai, H.-W., Jing, J.-N., Zhou, J.-Y., Zhang, C.-Y., & You, S.-Y. (2004). A novel fusion protein of IP10-scFv retains antibody specificity and chemokine function. Biochemical and Biophysical Research Communications, 320(2), 506–513. https://doi.org/https://doi.org/10.1016/j.bbrc.2004.05.193
   PubMed Web of Science ®Google Scholar
• Hansen, M., Wind, T., Blouse, G. E., Christensen, A., Petersen, H. H., Kjelgaard, S., Mathiasen, L., Holtet, T. L., & Andreasen, P. A. (2005). A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition. The Journal of Biological Chemistry, 280(46), 38424–38437. https://doi.org/https://doi.org/10.1074/jbc.M505933200
   PubMed Web of Science ®Google Scholar
• Hess, C., & Neri, D. (2014). Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications. Experimental Biology and Medicine, 239(7), 842–852. https://doi.org/https://doi.org/10.1177/1535370214536667
   Web of Science ®Google Scholar
• Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988). Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proceedings of the National Academy of Sciences of the United States of America, 85(16), 5879–5883. https://doi.org/https://doi.org/10.1073/pnas.85.16.5879
   PubMed Web of Science ®Google Scholar
• Illy, C., Quraishi, O., Wang, J., Purisima, E., Vernet, T., & Mort, J. S. (1997). Role of the occluding loop in cathepsin B activity. The Journal of Biological Chemistry, 272(2), 1197–1202. https://doi.org/https://doi.org/10.1074/jbc.272.2.1197
   PubMed Web of Science ®Google Scholar
• Jiang, T., Zhuang, J., Duan, H., Luo, Y., Zeng, Q., Fan, K., Yan, H., Lu, D., Ye, Z., Hao, J., Feng, J., Yang, D., & Yan, X. (2012). CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood, 120(11), 2330–2339. https://doi.org/https://doi.org/10.1182/blood-2012-01-406108
   PubMed Web of Science ®Google Scholar
• Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews. Cancer, 9(4), 239–252. https://doi.org/https://doi.org/10.1038/nrc2618
   PubMed Web of Science ®Google Scholar
• Keshtvarz, M., Salimian, J., Yaseri, M., Bathaie, S. Z., Rezaie, E., Aliramezani, A., Norouzbabaei, Z., Amani, J., & Douraghi, M. (2017). Bioinformatic prediction and experimental validation of a PE38-based recombinant immunotoxin targeting the Fn14 receptor in cancer cells. Immunotherapy, 9(5), 387–400. https://doi.org/https://doi.org/10.2217/imt-2017-0008
   PubMed Web of Science ®Google Scholar
• Kessenbrock, K., Plaks, V., & Werb, Z. (2010). Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell, 141(1), 52–67. https://doi.org/https://doi.org/10.1016/j.cell.2010.03.015
   PubMed Web of Science ®Google Scholar
• Khafaei, M., Rezaie, E., Mohammadi, A., Shahnazi Gerdehsang, P., Ghavidel, S., Kadkhoda, S., Zorrieh Zahra, A., Forouzanfar, N., Arabameri, H., & Tavallaie, M. (2019). miR‐9: From function to therapeutic potential in cancer. Journal of Cellular Physiology, 234(9), 14651–14665.
   Web of Science ®Google Scholar
• Kinoh, H., Inoue, M., Komaru, A., Ueda, Y., Hasegawa, M., & Yonemitsu, Y. (2009). Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies. Gene Therapy, 16(3), 392–403. https://doi.org/https://doi.org/10.1038/gt.2008.167
   PubMed Web of Science ®Google Scholar
• Kozakov, D., Beglov, D., Bohnuud, T., Mottarella, S. E., Xia, B., Hall, D. R., & Vajda, S. (2013). How good is automated protein docking? Proteins, 81(12), 2159–2166. https://doi.org/https://doi.org/10.1002/prot.24403
   PubMed Web of Science ®Google Scholar
• Kridel, S. J., Chen, E., Kotra, L. P., Howard, E. W., Mobashery, S., & Smith, J. W. (2001). Substrate hydrolysis by matrix metalloproteinase-9. The Journal of Biological Chemistry, 276(23), 20572–20578. https://doi.org/https://doi.org/10.1074/jbc.M100900200
   PubMed Web of Science ®Google Scholar
• Krieger, E., Koraimann, G., & Vriend, G. (2002). Increasing the precision of comparative models with YASARA NOVA – A self-parameterizing force field. Proteins, 47(3), 393–402.
   PubMed Web of Science ®Google Scholar
• Laskowski, R. A. (2001). PDBsum: Summaries and analyses of PDB structures. Nucleic Acids Research, 29(1), 221–222. https://doi.org/https://doi.org/10.1093/nar/29.1.221
   PubMed Web of Science ®Google Scholar
• List, T., & Neri, D. (2013). Immunocytokines: A review of molecules in clinical development for cancer therapy. Clinical Pharmacology: Advances and Applications, 5(Suppl 1), 29.
   PubMedGoogle Scholar
• Lobanov, M. Y., Bogatyreva, N. S., & Galzitskaya, O. V. (2008). Radius of gyration as an indicator of protein structure compactness. Molecular Biology, 42(4), 623–628. https://doi.org/https://doi.org/10.1134/S0026893308040195
   Web of Science ®Google Scholar
• Mason, S. D., & Joyce, J. A. (2011). Proteolytic networks in cancer. Trends in Cell Biology, 21(4), 228–237. https://doi.org/https://doi.org/10.1016/j.tcb.2010.12.002
   PubMed Web of Science ®Google Scholar
• Melero, I., Rouzaut, A., Motz, G. T., & Coukos, G. T. (2014). T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy. Cancer Discovery, 4(5), 522–526. https://doi.org/https://doi.org/10.1158/2159-8290.CD-13-0985
   PubMed Web of Science ®Google Scholar
• Mohammadi, M., Nejatollahi, F., Ghasemi, Y., & Faraji, S. N. (2017). Anti-metastatic and anti-invasion effects of a specific anti-MUC18 scFv antibody on breast cancer cells. Applied Biochemistry and Biotechnology, 181(1), 379–390. https://doi.org/https://doi.org/10.1007/s12010-016-2218-1
   PubMed Web of Science ®Google Scholar
• Mohammadi, M., Nejatollahi, F., Sakhteman, A., & Zarei, N. (2016). Insilico analysis of three different tag polypeptides with dual roles in scFv antibodies. Journal of Theoretical Biology, 402, 100–106. https://doi.org/https://doi.org/10.1016/j.jtbi.2016.04.016
   PubMed Web of Science ®Google Scholar
• Musil, D., Zucic, D., Turk, D., Engh, R. A., Mayr, I., Huber, R., Popovic, T., Turk, V., Towatari, T., & Katunuma, N. (1991). The refined 2.15 A X-ray crystal structure of human liver cathepsin B: The structural basis for its specificity. The EMBO Journal, 10(9), 2321–2330.
   PubMed Web of Science ®Google Scholar
• Osenga, K. L., Hank, J. A., Albertini, M. R., Gan, J., Sternberg, A. G., Eickhoff, J., Seeger, R. C., Matthay, K. K., Reynolds, C. P., Twist, C., Krailo, M., Adamson, P. C., Reisfeld, R. A., Gillies, S. D., & Sondel, P. M. (2006). A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children’s Oncology Group. Clinical Cancer Research, 12(6), 1750–1759. https://doi.org/https://doi.org/10.1158/1078-0432.CCR-05-2000
   PubMed Web of Science ®Google Scholar
• Papadia, F., Basso, V., Patuzzo, R., Maurichi, A., Di Florio, A., Zardi, L., Ventura, E., González-Iglesias, R., Lovato, V., Giovannoni, L., Tasciotti, A., Neri, D., Santinami, M., Menssen, H. D., & De Cian, F. (2013). Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. Journal of Surgical Oncology, 107(2), 173–179. https://doi.org/https://doi.org/10.1002/jso.23168
   PubMed Web of Science ®Google Scholar
• Pasche, N., & Neri, D. (2012). Immunocytokines: A novel class of potent armed antibodies. Drug Discovery Today, 17(11-12), 583–590. https://doi.org/https://doi.org/10.1016/j.drudis.2012.01.007
   PubMed Web of Science ®Google Scholar
• Pédelacq, J.-D., Cabantous, S., Tran, T., Terwilliger, T. C., & Waldo, G. S. (2006). Engineering and characterization of a superfolder green fluorescent protein. Nature Biotechnology, 24(1), 79–88. https://doi.org/https://doi.org/10.1038/nbt1172
   PubMed Web of Science ®Google Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera – A visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/https://doi.org/10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Podobnik, M., Kuhelj, R., Turk, V., & Turk, D. (1997). Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen. Journal of Molecular Biology, 271(5), 774–788. https://doi.org/https://doi.org/10.1006/jmbi.1997.1218
   PubMed Web of Science ®Google Scholar
• Reddy Chichili, V. P., Kumar, V., & Sivaraman, J. (2013). Linkers in the structural biology of protein-protein interactions. Protein Science, 22(2), 153–167. https://doi.org/https://doi.org/10.1002/pro.2206
   PubMed Web of Science ®Google Scholar
• Rezaie, E., Amani, J., Pour, A. B., & Hosseini, H. M. (2020). A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency. European Journal of Pharmacology, 870, 172912.
   PubMed Web of Science ®Google Scholar
• Rezaie, E., Mohammadi, M., Sakhteman, A., Bemani, P., & Ahrari, S. (2018). Application of molecular dynamics simulations to design a dual-purpose oligopeptide linker sequence for fusion proteins. Journal of Molecular Modeling, 24(11), 313. https://doi.org/https://doi.org/10.1007/s00894-018-3846-x
   PubMed Web of Science ®Google Scholar
• Rezaie, E., Nekoie, H., Miri, A., Oulad, G., Ahmadi, A., Saadati, M., Bozorgmehr, M., Ebrahimi, M., & Salimian, J. (2019). Different frequencies of memory B-cells induced by tetanus, botulinum, and heat-labile toxin binding domains. Microbial Pathogenesis, 127, 225–232. https://doi.org/https://doi.org/10.1016/j.micpath.2018.12.003
   PubMed Web of Science ®Google Scholar
• Rezaie, E., Pour, A. B., Amani, J., & Hosseini, H. M. (2020). Bioinformatics predictions, expression, purification and structural analysis of the PE38KDEL-scfv immunotoxin against EPHA2 receptor. International Journal of Peptide Research and Therapeutics, 26(2), 979–996.
   Web of Science ®Google Scholar
• Schmitz, J., Gilberg, E., Loser, R., Bajorath, J., Bartz, U., & Gutschow, M. (2019). Cathepsin B: Active site mapping with peptidic substrates and inhibitors. Bioorganic & Medicinal Chemistry, 27(1), 1–15. https://doi.org/https://doi.org/10.1016/j.bmc.2018.10.017
   PubMed Web of Science ®Google Scholar
• Sloane, B., Yan, S., Podgorski, I., Linebaugh, B., Cher, M., Mai, J., Cavallomedved, D., Sameni, M., Dosescu, J., & Moin, K. (2005). Cathepsin B and tumor proteolysis: Contribution of the tumor microenvironment. Seminars in Cancer Biology, 15(2), 149–157.
   PubMed Web of Science ®Google Scholar
• Sun, D., Sun, M., Zhu, W., Wang, Z., Li, Y., & Ma, J. (2015). The anti-cancer potency and mechanism of a novel tumor-activated fused toxin, DLM. Toxins, 7(2), 423–438. https://doi.org/https://doi.org/10.3390/toxins7020423
   PubMed Web of Science ®Google Scholar
• Tandon, A., & Sinha, S. (2011). Structural insights into the binding of MMP9 inhibitors. Bioinformation, 5(8), 310–314. https://doi.org/https://doi.org/10.6026/97320630005310
   PubMedGoogle Scholar
• Taylor, A., Verhagen, J., Blaser, K., Akdis, M., & Akdis, C. A. (2006). Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of T regulatory cells. Immunology, 117(4), 433–442. https://doi.org/https://doi.org/10.1111/j.1365-2567.2006.02321.x
   PubMed Web of Science ®Google Scholar
• Vacchelli, E., Galluzzi, L., Eggermont, A., Galon, J., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial watch: Immunostimulatory cytokines. Oncoimmunology, 1(4), 493–506. https://doi.org/https://doi.org/10.4161/onci.20459
   PubMed Web of Science ®Google Scholar
• Vessillier, S., Adams, G., & Chernajovsky, Y. (2004). Latent cytokines: Development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3. Protein Engineering, Design & Selection, 17(12), 829–835. https://doi.org/https://doi.org/10.1093/protein/gzh097
   PubMed Web of Science ®Google Scholar
• Wang, Z., Xu, Q., Zhang, N., Du, X., Xu, G., & Yan, X. (2020). CD146, from a melanoma cell adhesion molecule to a signaling receptor. Signal Transduction and Targeted Therapy, 5(1), 1–15.
   PubMed Web of Science ®Google Scholar
• Xu, D., Jaroszewski, L., Li, Z., & Godzik, A. (2014). AIDA: Ab initio domain assembly server. Nucleic Acids Research, 42, W308–W313. https://doi.org/https://doi.org/10.1093/nar/gku369
   PubMed Web of Science ®Google Scholar
• Xu, D., Jaroszewski, L., Li, Z., & Godzik, A. (2015). AIDA: Ab initio domain assembly for automated multi-domain protein structure prediction and domain-domain interaction prediction. Bioinformatics, 31(13), 2098–2105. https://doi.org/https://doi.org/10.1093/bioinformatics/btv092
   PubMed Web of Science ®Google Scholar
• Xu, D., & Zhang, Y. (2011). Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. Biophysical Journal, 101(10), 2525–2534. https://doi.org/https://doi.org/10.1016/j.bpj.2011.10.024
   PubMed Web of Science ®Google Scholar
• Xu, D., & Zhang, Y. (2012). Ab initio protein structure assembly using continuous structure fragments and optimized knowledge-based force field. Proteins, 80(7), 1715–1735. https://doi.org/https://doi.org/10.1002/prot.24065
   PubMed Web of Science ®Google Scholar
• Yamane, B. H., Hank, J. A., Albertini, M. R., & Sondel, P. M. (2009). The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opinion on Investigational Drugs, 18(7), 991–1000. https://doi.org/https://doi.org/10.1517/13543780903048911
   PubMed Web of Science ®Google Scholar
• Zeng, P., Li, H., Lu, P.-H., Zhou, L.-N., Tang, M., Liu, C.-Y., & Chen, M.-B. (2017). Prognostic value of CD146 in solid tumor: A systematic review and meta-analysis. Scientific Reports, 7(1), 1–7.
   PubMedGoogle Scholar
• Zhao, H. L., Yao, X. Q., Xue, C., Wang, Y., Xiong, X. H., & Liu, Z. M. (2008). Increasing the homogeneity, stability and activity of human serum albumin and interferon-α2b fusion protein by linker engineering. Protein Expression and Purification, 61(1), 73–77. https://doi.org/https://doi.org/10.1016/j.pep.2008.04.013
   PubMed Web of Science ®Google Scholar